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Background: We previously identiﬁed MGL_1304 secreted by Malassezia globosa as a sweat antigen for
patients with atopic dermatitis (AD) and cholinergic urticaria (ChU). However, purifying native
MGL_1304 from human sweat or culture supernatant of M. globosa (sup-MGL_1304) is costly and time-
consuming. Moreover, recombinant MGL_1304 expressed by using Escherichia coli (TF-rMGL_1304) needs
a large chaperon protein and lacks the original glycosylation of yeasts. Thus, we generated a recombinant
MGL_1304 by Pichia pastoris (P-rMGL_1304) and investigated its characteristic features.
Methods: Recombinant MGL_1304 proteins expressed by E. coli and P. pastoriswere generated. Properties
of these recombinants and native antigens were compared by western blot analysis, histamine release
tests (HRT) of patients with AD and ChU, and b-hexosaminidase release tests with RBL-48 cells. P-
rMGL_1304-speciﬁc IgE in sera of patients with AD were measured by sandwich ELISA.
Results: Western blot analysis revealed that IgE of patients with AD bound to all MGL_1304 recombi-
nants and native antigens. The histamine releasing ability of P-rMGL_1304 was 100 times higher than
that of TF-rMGL_1304, and was comparable to that of sup-MGL_1304. Degranulation rates of RBL-48
cells, sensitized with sera of patients with AD in response to the stimulation of P-rMGL_1304, were
comparable to those of sup-MGL_1304, whereas those of TF-rMGL_1304 were relatively weak. The levels
of P-rMGL_1304-speciﬁc IgE in sera of patients with AD were correlated with their disease severities.
Conclusions: P-rMGL_1304 has an antigenicity comparable to the native antigen, and is more useful than
TF-rMGL_1304, especially in HRT and degranulation assay of RBL-48 cells.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction
Atopic dermatitis (AD) is a chronic inﬂammatory skin disease
with pruritus and characteristic distribution and morphology of
skin lesions.1,2 Sweat is one of the exacerbation factors of AD,3,4 and
reported as an antigen for type I allergy in 77% patients with AD.5
Cholinergic urticaria (ChU) is a subtype of urticaria where small
reddish wheals develop in response to sweating or the increase of
body core temperature. We previously reported that the puriﬁed
sweat antigen induces degranulation of basophils of patients with
AD and those with ChU.6 Type I antigenicity of the puriﬁed sweat
antigenwas endorsed by the sensitization of a humanmast cell liney, Integrated Health Sciences,
a University, 1-2-3 Kasumi,
jp (M. Hide).
ety of Allergology.
rgology. Production and hosting by Elsewith IgE puriﬁed from sera of patients with AD and neutralization
of the histamine releasing activity of the puriﬁed sweat by sera of
the patients.5 We ﬁnally have identiﬁed MGL_1304 secreted by
Malassezia globosa as a sweat antigen for patients with AD and
ChU.7,8 We also reported that levels of MGL_1304-speciﬁc IgE in
sera of patients with AD were signiﬁcantly higher than those of
healthy subjects and correlated with the severity of AD by ELISAs
using puriﬁed MGL_1304 and recombinant MGL_1304 expressed
by Escherichia coli (TF-rMGL_1304).8 In Japan, a histamine release
test (HRT) against sweat antigen, which mainly contains
MGL_1304, has been commercially available since 2010 (Allerport®
HRT, MANUFACTURER: Shionogi & Co., Ltd., Osaka, Japan,
DISTRIBUTOR: Kyowa Medex Co., Ltd., Tokyo, Japan). However,
puriﬁcation of MGL_1304 from human sweat or culture superna-
tant ofM. globosa is both time-consuming and costly. Alternatively,
TF-rMGL_1304 can be generated at low cost. However, it needs a
large chaperon protein to be solubilized and lacks the original
glycosylation of yeasts. Thus, another recombinant protein, that isvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1. (A) P-rMGL_1304, TF-rMGL_1304, supMGL_1304 and P-rMUCL1 were electro-
phoresed and stained with CBB. (B) The secreted and intracellular forms of P-
rMGL_1304 were electrophoresed and blotted with anti-His-tag antibody. A repre-
sentative data of three independent experiments was shown for each panel.
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tional structure, is desirable for clinical applications. In this study,
we generated recombinant MGL_1304 using a yeast cell line, Pichia
pastoris, and studied its features and usefulness for clinical appli-
cations to patients with sweat allergy.
Methods
Subjects
One-hundred thirty ﬁve subjects were included in this study.
Nineteen patients with AD and 11 patients with ChU (15 men
and 15 women; mean age ± SD: 31.7 ± 16.4 years) were inves-
tigated by HRT, and 34 patients with AD (13 men and 21 women;
mean age ± SD: 26.2 ± 13.0 years; mean serum IgE ± SD,
4236.8 ± 5472.6 IU/ml) were studied by b-hexosaminidase
release of RBL-48 cells. Fifty seven patients with AD (32 men and
25 women; mean age ± SD: 29.8 ± 11.7 years) and 18 healthy
individuals (9 men and 9 women; mean age ± SD: 26.6 ± 7.2
years) were subjected to the measurement of the P-rMGL_1304-
speciﬁc IgE in sera by the sandwich ELISA. Blood samples from
patients with AD and ChU were obtained following written
informed consent, and the studies were approved by the Ethics
Committee of Hiroshima University Institute of Biomedical &
Health Sciences.
Generation of recombinant MGL_1304 protein
A recombinant MGL_1304 using P. pastoris (P-rMGL_1304) was
generated with EasySelect™ Pichia Expression Kit (Invitrogen,
Carlsbad, CA, USA). The cDNA of MGL_1304 were subcloned into
pPICZa-A Pichia expression vector and the plasmid DNA were
prepared using One Shot® TOP10 Chemically Competent E. coli
(Invitrogen). P. pastoris (G-115 strain) were transformed using the
Pichia EasyComp™ procedure. After conﬁrming that the phenotype
of the transformants was Mutþ, recombinant Pichia strains were
cultured for 4 or 5 days. For the secreted recombinant protein (P-
rMGL_1304), the culture supernatant was puriﬁed by batchmethod
using nickel resin (ProBond™, GE Healthcare, Buckinghamshire,
UK) according to the manufacturer's instruction. For the intracel-
lular P-rMGL_1304, cell pellets was lysed by the disposable ho-
mogenizer (Treff pellet mixers®, Treff AG, Degersheim,
Switzerland), and then puriﬁed with the same procedure as the
secreted recombinant protein. A recombinant human mucin-like 1
(P-rMUCL1), which has not been shown histamine release ability to
peripheral blood basophils of patients with AD, was generated as a
negative control with the same procedures as P-rMGL_1304.
Trigger factor (TF)-fused rMGL_1304 protein (TF-rMGL_1304) was
prepared as described previously.7
Preparation of native antigen (sup-MGL_1304)
MGL_1304 in the culture supernatant of M. globosa (sup-
MGL_1304) was isolated as described previously.7
Determination of protein concentration
The concentrations of P-rMGL_1304, P-rMUCL1, sup-MGL_1304,
and TF-rMGL_1304 were measured by bicinchoninic acid (BCA)
protein assay. The immunological amount of MGL_1304 contained
in P-rMGL_1304 was determined by the sandwich ELISA as
described previously,8 with a slight modiﬁcation. Brieﬂy, 10 mg/ml
of the mouse monoclonal IgG antibody against puriﬁed sweat an-
tigen (Smith-2) was used as capture antibody, and 1:40 diluted the
AD standard serum was used as detection antibody. Theconcentration of sup-MGL_1304 measured by BCA protein assay
was used as standard.
Western blot analysis
Samples were loaded into an SDS-PAGE gel and transferred to
a polyvinylidene ﬂuoride membrane as reported elsewhere.7
The membranes were incubated with anti-Penta-His antibody
(Qiagen, Hilden, Germany), 1:100 diluted sera of patients with
AD or healthy individuals, or 1 mg/ml of Smith-2 at 4 C over-
night. The membrane-bound primary antibodies were visualized
with horseradish peroxidase-conjugated secondary antibodies
and chemiluminescence. All images were adjusted by using
“auto levels” in Adobe Photoshop (Adobe Systems, San Jose, CA,
USA).
Histamine release test with peripheral blood basophils of patients
with AD or ChU
HRTs with peripheral blood basophils were performed as
described previously.9 Cells were stimulated with 1 mg/ml of goat
anti-human IgE antibody (Bethyl Laboratories, Montgomery, TX,
USA) and various concentrations of TF-rMGL_1304, P-rMGL_1304,
sup-MGL_1304, or P-rMUCL1.
Measurement of b-hexosaminidase release of RBL-48 cells
RBL-48 cells, a rat basophilic leukemia cell line expressing the
alpha chain of human high-afﬁnity IgE receptor on the cell surface,
were provided by Dr John Hakimi (F. Hoffmann-La Roche, Nutley,
NJ, USA).10 RBL-48 cells (0.3  106/ml) were sensitized with 30
times-diluted sera of patients with AD at 37 C overnight. After the
incubation, culture medium was removed and cells were washed
for three times with PIPES-buffered saline (25 mM PIPES: pH 7.2,
119 mM NaCl, 5 mM KCl, 5.6 mM glucose, 0.4 mM MgCl2, 1 mM
CaCl2, 0.1% BSA) and incubated with the same buffer at 37 C for
10 min. The cells were then stimulated with 1 mg/ml of TF-
rMGL_1304 and various concentrations of P-rMGL_1304 or sup-
MGL_1304 for 15 min. The exocytosis of cells was quantiﬁed by
measuring the hexosaminidase activity of the supernatants as
previously described.11
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Fig. 3. P-rMGL_1304, TF-rMGL_1304, sup-MGL_1304, and P-rMUCL1 were electro-
phoresed and blotted with anti-His-Tag antibody and Smith-2. A representative data of
three independent experiments was shown for each panel.
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healthy individuals
P-rMGL_1304-speciﬁc IgE in sera of patients with AD and
healthy individuals were measured by sandwich ELISA as described
previously,8 with a slight modiﬁcation. In this study, 1 mg/ml of P-
rMGL_1304 was used as the antigen, instead of 1 mg/ml of QRX
(puriﬁed MGL_1304 from human sweat).
Results
Antigenecity of P-rMGL_1304
P-rMGL_1304, TF-rMGL_1304, sup-MGL_1304, and P-rMUCL1
used in the following experiments were stained with Coomassie
Brilliant Blue G-250 (Fig. 1A). The molecular mass of P-rMGL_1304
was approximately 26 kDa. The secreted protein and intracellular
protein, which were both detected by anti-His-tag antibody,
migrated similarly in SDS-PAGE (Fig. 1B). Serum IgE of AD recog-
nized TF-rMGL_1304, P-rMGL_1304, and sup-MGL_1304, but not
the negative control, P-rMUCL1, and serum IgE of a healthy indi-
vidual hardly recognized those proteins (Fig. 2). Monoclonal anti-
bodies against MGL_1304 showed a diversity of afﬁnities to these
recombinants and native protein. Smith-2 recognized P-
rMGL_1304 and supMGL_1304 stronger than TF-rMGL_1304
(Fig. 3). As expected, P-rMUCL1 was not recognized by Smith-2
(Fig. 3).
P-rMGL_1304 evokes histamine release from basophils of patients
with AD or ChU at the concentration equivalent to sup-MGL_1304
Both P-rMGL_1304 and TF-rMGL_1304 showed histamine
release from basophils of patients with AD or ChU. However, the
concentrations of P-rMGL_1304 and TF-rMGL_1304, for the
maximum histamine release were around 0.01 mg/ml and 1 mg/
ml, respectively (Fig. 4A). Therefore, the histamine releasing
ability of P-rMGL_1304 was 100 times higher than that of TF-
rMGL_1304 in weight/ml basis. Taking into account the102
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Fig. 2. P-rMGL_1304, TF-rMGL_1304, sup-MGL_1304, and P-rMUCL1 were electro-
phoresed and blotted with serum of a patient with AD and healthy individual. A
representative data of three independent experiments was shown.molecular mass of these protein, 26 kDa for P-rMGL_1304 and
75 kDa for TF-rMGL_1304, the difference is approximately 30
times in terms of molecular basis. P-rMUCL1, a negative control
protein produced by P. pastoris, did not evoke histamine release
from basophils of patients with AD or ChU at any concentration
(Fig. 4A). The histamine releasing abilities of P-rMGL_1304 and
sup-MGL_1304 were equivalent, when their immunological
concentrations were measured by sandwich ELISA (see Methods)
(Fig. 4B). In 19 AD patients and 11 ChU patients, the correlation
coefﬁcient of percent histamine release between sup-MGL_1304
and P-rMGL_1304, and that between sup-MGL_1304 and TF-
rMGL_1304 were 0.985 and 0.982, respectively, when periph-
eral blood basophils were stimulated with 10 ng/ml of P-
rMGL_1304, 10 ng/ml of sup-MGL_1304, or 1 mg/ml of TF-
rMGL_1304 (Fig. 4C). There were no signiﬁcant differences in
clinical characteristics, such as disease severity and total serum
IgE between the patients who reacted to MGL_1304 and the
patients who did not react to MGL_1304.P-rMGL_1304 and sup-MGL_1304 similarly cause degranulation of
RBL-48 cells
The stimulation of sup-MGL_1304 and P-rMGL_1304 evoked
degranulation of RBL-48 cells sensitized with sera of patients with
AD. The doseeresponse curves of these two recombinants were
quite similar, when compared by immunological concentrations of
MGL_1304 (Fig. 5A). The optimal concentration of both sup-
MGL_1304 and P-rMGL_1304 for the degranulation of RBL-48 was
approximately 10 ng/ml, which is similar to that for HRT. On the
other hand, TF-rMGL1304 induced no or only small amount of
degranulation of RBL-48 cells. The stimulation of P-rMUCL1 did not
induce degranulation of RBL-48 cells (data not shown). In 34 pa-
tients with AD, the correlation coefﬁcient of percent release of b-
hexosaminidase between sup-MGL_1304 and P-rMGL_1304, and
that between sup-MGL_1304 and TF-rMGL_1304 were 0.885 and
0.627, respectively, when RBL-48 cells were stimulated with 10 ng/
ml of P-rMGL_1304, 10 ng/ml of sup-MGL_1304, or 1 mg/ml of TF-
rMGL_1304 (Fig. 5B).
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Fig. 6. (A) A standard curve of P-rMGL_1304-speciﬁc IgE plotted by using AD standard serum in ELISA. (B) Serum levels of P-rMGL_1304-speciﬁc IgE in patients with AD and healthy
individuals were plotted and analyzed by ManneWhitney test. (C) The levels of P-rMGL_1304-speciﬁc IgE in sera of patients with various severities of AD and healthy individuals
were analyzed by Spearman rank correlation.
T. Kan et al. / Allergology International 64 (2015) 266e271270P-rMGL_1304-speciﬁc IgE of patients with AD is correlated with
severity of AD
We successfully measured MGL_1304-speciﬁc IgE in sera of
patients with AD by the ELISA system using P-rMGL_1304 as the
antigen, instead of QRX (Fig. 6A). As the levels of IgE against puri-
ﬁed MGL_1304 and those against TF-rMGL_1304 reported previ-
ously, the levels of P-rMGL_1304-speciﬁc IgE in sera of patients
with AD were signiﬁcantly higher than those of healthy individuals
(Fig. 6B) and correlated with the severity of AD (Fig. 6C).
Discussion
In this study, we generated recombinant MGL_1304 by using
P. pastoris and investigated its antigenicity by comparing with TF-
rMGL_1304 produced by E. coli and native MGL_1304. In western
blot analysis, serum IgE of patients with AD similarly bound to these
proteins. However, in degranulation assays using peripheral blood
basophils and RBL-48 cells, P-rMGL_1304, but not TF-rMGL_1304,
showed an antigenicity comparable to the native protein.
P. pastoris is a methylotrophic yeast which widely used for
heterologous protein expression.12,13 The AOX1 gene of P. pastoris
metabolizes methanol in the medium as its sole source of carbon.
P. pastoris is easy to culture, and the recombinant protein is readily
puriﬁed in large quantities at a low cost, because almost no other
exogenous proteins are contained in culture medium for P. pastoris.
The recombinant protein is produced intracellularly or extracellu-
larly, with many eukaryotic posttranslational modiﬁcations such as
glycosylation, disulﬁde bond formation and proteolytic process-
ing.12,13 In comparison with other protein expression systems such
as mammalian cells or insect cells, it is superior in terms of costs
and yield of proteins.
The antigenicity of P-rMGL_1304 was similar to the native
protein, but it was slightly different from TF-rMGL_1304 analyzed
by western blot analysis using the monoclonal antibodies. Theafﬁnity for monoclonal antibodies might be altered by the post-
translational modiﬁcation by yeast. Tag and chaperon proteins
connected to MGL_1304 may also interfere the antigeneantibody
interactions. P-rMGL_1304 possesses a polyhistidine tag in its C-
terminus, and TF-rMGL_1304 possesses a chaperon protein, TF, in
its N-terminus. Binding studies with various truncated proteins of
MGL_1304 revealed that Smith-2 binds to the N-terminal region of
MGL_1304,7 suggesting that N-terminal TF might attenuate the
binding of monoclonal Smith-2, but not polyclonal IgE of AD pa-
tients, to TF-rMGL_1304.
The advantage of diagnosing sweat allergy by using humanized
mast cells is the functional evaluation of IgE against MGL_1304
without requiring fresh basophils from patients. However, TF-
rMGL_1304 did not cause degranulation of RBL-48 cells bearing
serum IgE of patients with AD which was shown to bind to TF-
rMGL_1304 in western blot analysis. On the other hand, P-
rMGL_1304 causes equivalent degranulation of RBL-48 cells, sug-
gesting that P-rMGL_1304 is more similar to the native protein than
TF-rMGL_1304. The reason for the difference between these
recombinants in the assay with RBL-48 is unknown. This assay may
not represent activities of basophils and mast cells of patients
themselves, but may overcome disadvantages of HRT such as the
necessity of discontinuation of drugs and failure of evaluation of
the subjects with non-responding basophils.
In conclusion, it is considered that P-rMGL_1304 has the
conformational structure and antigenicity quite similar to native
MGL_1304. We believe that this recombinant protein not only
improves the diagnosis of sweat allergy, but also facilitates the
development of new desensitization therapy against MGL_1304 for
the future.
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